Literature DB >> 1989648

Expression of ecto-5'-nucleotidase (CD73) in normal mammary gland and in breast carcinoma.

K H Krüger1, L F Thompson, M Kaufmann, P Möller.   

Abstract

Ecto-5'-nucleotidase (ecto-5'-NT) is a phosphatidylinositol anchored membrane structure recently defined as the lymphocyte differentiation antigen CD73. Using CD73 (1E9.28.1) monoclonal antibody, normal mammary gland and breast carcinoma were immunohistochemically investigated for ecto-5'-NT expression. In normal breast epithelium, CD73 was differentially expressed in lobular, ductal and myoepithelial cells and was most frequently detected in the myoepithelial compartment. The glandular stroma contained fibrocytes, a subset of which was also CD73-positive. Among 102 unselected breast carcinoma primary lesions, only 9 contained CD73-positive tumour cells, whereas in 95 cases, stromal fibroblasts and fibrocytes showed variable degrees of CD73 expression. The extent of stromal CD73 expression correlated positively with the estrogen receptor (ER) status of the tumour (P less than 0.038). We conclude that ecto-5'-NT-expression reflects a still unknown state of activity of normal breast epithelium which is lost in the majority of carcinomas derived therefrom. It may also be indicative of some functional activity of stromal fibroblasts which is significantly enhanced in ER-positive carcinomas.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1989648      PMCID: PMC1971649          DOI: 10.1038/bjc.1991.23

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  Specific release of plasma membrane enzymes by a phosphatidylinositol-specific phospholipase C.

Authors:  M G Low; J B Finean
Journal:  Biochim Biophys Acta       Date:  1978-04-20

2.  Ecto-5'-nucleotidase can provide the total purine requirements of mitogen-stimulated human T cells and rapidly dividing human B lymphoblastoid cells.

Authors:  L F Thompson
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

3.  Quality control for estrogen receptor quantification by dextran-coated charcoal assay: a single laboratory's experience.

Authors:  S Raam; R Gelman; J Faulkner; G M White; J L Cohen
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

4.  A glycophospholipid anchor is required for Qa-2-mediated T cell activation.

Authors:  P J Robinson; M Millrain; J Antoniou; E Simpson; A L Mellor
Journal:  Nature       Date:  1989-11-02       Impact factor: 49.962

Review 5.  Transforming growth factors beta.

Authors:  J J Hsuan
Journal:  Br Med Bull       Date:  1989-04       Impact factor: 4.291

6.  Development and properties of a monoclonal antibody specific for human ecto-5'-nucleotidase.

Authors:  U Kummer; J Mysliwietz; W Gutensohn; S Buschette; H Jahn; D Neuser; R Munker
Journal:  Immunobiology       Date:  1984-03       Impact factor: 3.144

7.  Lymphocyte ecto-5'-nucleotidase activity in infancy: increasing activity in peripheral blood B cells precedes their ability to synthesize IgG in vitro.

Authors:  J F Bastian; J M Ruedi; G A MacPherson; H E Golembesky; R D O'Connor; L F Thompson
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

8.  Inositol is a constituent of detergent-solubilized immunoaffinity-purified rat liver 5'-nucleotidase.

Authors:  E M Bailyes; M A Ferguson; C A Colaco; J P Luzio
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

9.  5'-Nucleotidase from rat heart.

Authors:  Y Naito; J M Lowenstein
Journal:  Biochemistry       Date:  1981-09-01       Impact factor: 3.162

10.  Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.

Authors:  H J BLOOM; W W RICHARDSON
Journal:  Br J Cancer       Date:  1957-09       Impact factor: 7.640

View more
  16 in total

Review 1.  5'-Nucleotidase: molecular structure and functional aspects.

Authors:  H Zimmermann
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

2.  CD antigens as promising tools for the functional analysis of solid tumours.

Authors:  P Möller
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

3.  Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Authors:  Luca Antonioli; Gennady G Yegutkin; Pál Pacher; Corrado Blandizzi; György Haskó
Journal:  Trends Cancer       Date:  2016-02-01

4.  CD73s protection of epithelial integrity: Thinking beyond the barrier.

Authors:  Jessica L Bowser; Russell R Broaddus
Journal:  Tissue Barriers       Date:  2016-08-19

5.  CD73 participates in cellular multiresistance program and protects against TRAIL-induced apoptosis.

Authors:  Andrey Mikhailov; Alice Sokolovskaya; Gennady G Yegutkin; Hanne Amdahl; Anne West; Hideo Yagita; Riitta Lahesmaa; Linda F Thompson; Sirpa Jalkanen; Dmitry Blokhin; John E Eriksson
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

6.  Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry.

Authors:  Rikke Leth-Larsen; Rikke Lund; Helle V Hansen; Anne-Vibeke Laenkholm; David Tarin; Ole N Jensen; Henrik J Ditzel
Journal:  Mol Cell Proteomics       Date:  2009-03-24       Impact factor: 5.911

7.  Loss of CD73-mediated actin polymerization promotes endometrial tumor progression.

Authors:  Jessica L Bowser; Michael R Blackburn; Gregory L Shipley; Jose G Molina; Kenneth Dunner; Russell R Broaddus
Journal:  J Clin Invest       Date:  2015-12-07       Impact factor: 14.808

8.  Ecto-5'-nucleotidase (CD73) promotes tumor angiogenesis.

Authors:  Li Wang; Shaoxian Tang; Yingjian Wang; Siguang Xu; Jerry Yu; Xiuling Zhi; Zhouluo Ou; Jiayin Yang; Ping Zhou; Zhimin Shao
Journal:  Clin Exp Metastasis       Date:  2013-03-19       Impact factor: 5.150

9.  NT5E CpG island methylation is a favourable breast cancer biomarker.

Authors:  C Lo Nigro; M Monteverde; S Lee; L Lattanzio; D Vivenza; A Comino; N Syed; A McHugh; H Wang; C Proby; O Garrone; M Merlano; E Hatzimichael; E Briasoulis; O Gojis; C Palmieri; L Jordan; P Quinlan; A Thompson; T Crook
Journal:  Br J Cancer       Date:  2012-05-31       Impact factor: 7.640

10.  Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type.

Authors:  Steven Rust; Sandrine Guillard; Kris Sachsenmeier; Carl Hay; Max Davidson; Anders Karlsson; Roger Karlsson; Erin Brand; David Lowne; John Elvin; Matt Flynn; Gene Kurosawa; Robert Hollingsworth; Lutz Jermutus; Ralph Minter
Journal:  Mol Cancer       Date:  2013-02-13       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.